Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 24:2013:958724.
doi: 10.1155/2013/958724. eCollection 2013.

The role of epiretinal membrane on treatment of neovascular age-related macular degeneration with intravitreal bevacizumab

Zeynep Alkin  1 , Abdullah Ozkaya  1 , Ozen Ayranci Osmanbasoglu  1 , Alper Agca  1 , Yalcin Karakucuk  1 , Ahmet Taylan Yazici  1 , Ahmet Demirok  2
Affiliations

The role of epiretinal membrane on treatment of neovascular age-related macular degeneration with intravitreal bevacizumab

Zeynep Alkin et al. ScientificWorldJournal. .

Abstract

Purpose: To determine the effect of epiretinal membranes (ERM) on the treatment response and the number of intravitreal bevacizumab injections (IVB) in patients with neovascular age-related macular degeneration (nAMD).

Methods: A retrospective chart review was performed on 63 eyes of 63 patients. The patients were divided into AMD group (n = 35) and AMD/ERM group (n = 28). Best corrected visual acuity (BCVA) and central retinal thickness (CRT), as well as the number of injections, were evaluated.

Results: There was a significant improvement in BCVA at 3 months for the AMD and AMD/ERM groups (P = 0.02, P = 0.03, resp.). At 6, 12, and 18 months, BCVA did not change significantly in either of the groups compared to baseline (P > 0.05 for all). At 3, 6, 12, and 24 months, the AMD group had an improvement in BCVA (logMAR) of 0.09, 0.06, 0.06, and 0.03 versus 0.08, 0.07, 0.05, and 0.03 for the AMD/ERM group (P = 0.29, P = 0.88, P = 0.74, P = 0.85, resp.). A significant decrease in CRT occurred in both groups for all time points (P < 0.001 for all). The change in CRT was not statistically different between the two groups at all time points (P > 0.05 for all). The mean number of injections over 24 months was 8.8 in the AMD group and 9.2 in the AMD/ERM group (P = 0.76).

Conclusion: During 24 months, visual and anatomical outcomes of IVB in nAMD patients were comparable with those in nAMD patients with ERM with similar injection numbers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change in best corrected visual acuity (logMAR) from baseline and to the 3-, 6-, 12-, and 24-month follow-up in the AMD group and AMD/ERM group. (Respective intravitreal injections administered at months 0, 1, and 2 and then as per treatment protocol.)
Figure 2
Figure 2
Change in central retinal thickness (μm) from baseline and to the 3-, 6-, 12-, and 24-month follow-up in the AMD group and AMD/ERM group. (Respective intravitreal injections administered at months 0, 1, and 2 and then as per treatment protocol.)
See this image and copyright information in PMC

References

    1. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. I. Outline and major prevalence findings. American Journal of Epidemiology. 1977;106(1):17–32. - PubMed
    1. Klein R, Klein BEK, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104(1):7–21. - PubMed
    1. Klaver CCW, Wolfs RCW, Vingerling JR, Hofman A, de Jong PTVM. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Archives of Ophthalmology. 1998;116(5):653–658. - PubMed
    1. Adamis AP, Aiello LP, D’Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis. 1999;3(1):9–14. - PubMed
    1. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. American Journal of Ophthalmology. 2007;144(4):627–637. - PubMed

MeSH terms

Substances